Syndax Pharmaceuticals (NASDAQ:SNDX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.
Valuation and Earnings
This table compares Syndax Pharmaceuticals and Kamada's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Syndax Pharmaceuticals | $1.52 million | 703.23 | $-56,050,000.00 | ($1.84) | -12.04 |
Kamada | $127.19 million | 2.15 | $22.25 million | $0.55 | 11.16 |
Kamada has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Syndax Pharmaceuticals and Kamada, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Syndax Pharmaceuticals | 0 | 2 | 9 | 0 | 2.82 |
Kamada | 0 | 0 | 2 | 0 | 3.00 |
Syndax Pharmaceuticals presently has a consensus target price of $28.5455, indicating a potential upside of 28.82%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Syndax Pharmaceuticals.
Volatility and Risk
Syndax Pharmaceuticals has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Profitability
This table compares Syndax Pharmaceuticals and Kamada's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Syndax Pharmaceuticals | -4,656.63% | -77.47% | -52.27% |
Kamada | 15.60% | 12.89% | 10.66% |
Summary
Kamada beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.